Department of Thoracic Oncology, Kanagawa Cancer Center, Asahi-ku, Yokohama, Japan.
Anticancer Res. 2012 Apr;32(4):1453-6.
No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC).
Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m(2) and irinotecan at 50 mg/m(2) on days 1 and 8 every four weeks for four cycles.
Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease.
Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung.
尚无标准的化疗方案用于治疗大细胞神经内分泌癌（LCNEC）患者。
18 例肺 LCNEC 患者接受奈达铂（NP）50mg/m²和伊立替康 50mg/m²，每 4 周为一个周期，连用 4 个周期。
回顾性分析了 18 例 LCNEC 患者的数据。所有患者均为男性，体能状态 0 或 1 级，中位年龄为 68 岁（范围为 58-80 岁）。9 例患者在完全手术后接受了辅助化疗。14 例患者能够接受 4 个周期的奈达铂和伊立替康治疗。分别有 5.6%和 16.7%的患者发生了 4 级白细胞减少和中性粒细胞减少。4 例患者出现了 3 级非血液学毒性，如腹泻、结肠炎、十二指肠穿孔和心肌梗死。无治疗相关死亡病例。晚期疾病患者中，有 2 例患者达到完全缓解，4 例患者达到部分缓解，9 例患者的中位生存时间为 12.3 个月。
奈达铂联合伊立替康治疗肺 LCNEC 有效且安全。
